Abstract: The invention provides novel pharmaceutical compositions comprising the active ingredient propofol. Preferably, propofol is dissolved in at least one semifluorinated alkane. The compositions, which are preferably liquid or gel-like, may optionally comprise further excipients. They may be used as fill material in capsules, as buccal or nasal sprays, or as aerosols for pulmonary administration. They are particularly useful for the transmucosal administration of propofol.
Abstract: The invention provides semi-solid or liquid pharmaceutical compositions for topical administration to a finger- or toenail of a human. The compositions are useful for the delivery of active ingredients deep into the nail. Various active ingredients may be incorporated, such as antifungal agents, anti-infectives, anti-inflammatory agents, immunosuppressants, local anaesthetics, and retinoids.
Type:
Application
Filed:
May 24, 2012
Publication date:
May 22, 2014
Applicant:
NOVALIQ GMBH
Inventors:
Bernhard Gunther, Bastian Theisinger, Sonja Theisinger
Abstract: The invention provides liquid or semi-solid pharmaceutical compositions for topical administration comprising a semifluorinated alkane. The compositions are useful for the delivery of active ingredients into the deep layers of the skin or skin appendages. Various active ingredients may be incorporated, such as immunosuppressants, antiinfectives, antifungal agents, antiinflammatory agents, and retinoids.
Type:
Application
Filed:
May 24, 2012
Publication date:
April 10, 2014
Applicant:
NOVALIQ GMBH
Inventors:
Bernhard Gunther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer
Abstract: The invention provides novel pharmaceutical compositions for the treatment of keratoconjunctivitis sicca comprising liquid vehicles which include one or more semifluorinated alkanes. The compositions incorporate an active ingredient selected from the group of macrolide immunosuppressants. They can be administered topically into the eye. The invention further provides kits comprising such compositions.
Type:
Grant
Filed:
December 13, 2010
Date of Patent:
December 24, 2013
Assignee:
Novaliq GmbH
Inventors:
Bastian Theisinger, Sonja Theisinger, Bernhard Günther
Abstract: The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.
Abstract: The invention provides novel pharmaceutical compositions of macrolide immunosuppressants. The compositions comprise a hydrophilic component, a lipophilic component, and an amphiphilic component. Preferably, the compositions are formulated as liquid microemulsion. Furthermore, the invention provides uses of such compositions, such as for the topical treatment of inflammatory and autoimmune diseases. Methods for preparing the compositions are also provided.
Abstract: The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble and/or hydrolytically sensitive drug substances. The compositions are designed as suspensions and have superior physical properties which make them highly useful as pharmaceutical delivery systems. The compositions may be administered topically into the eye, or injected via the subcutaneous or intramuscular route. The invention further provides kits comprising such compositions.
Type:
Application
Filed:
October 18, 2011
Publication date:
October 10, 2013
Applicant:
Novaliq GmbH
Inventors:
Bastian Theisinger, Sonja Theisinger, Bernhard Günther
Abstract: The invention provides a novel aqueous composition for the storage and preservation of transplants, such as organ or tissue allografts. The composition comprises the compound N-octanoyl dopamine in solubilised form. The composition may also be administered as a pre-treatment of transplant donors. Moreover, it may be used in transplant recipients, optionally in combination with immunosuppressants.
Type:
Application
Filed:
August 16, 2011
Publication date:
June 6, 2013
Applicant:
NOVALIQ GMBH
Inventors:
Bastian Theisinger, Sonja Theisinger, Bernhard Günther
Abstract: The invention provides novel pharmaceutical compositions for the treatment of increased intraocular pressure based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble prostaglandin analogues. The compositions can be administered topically into the eye. The invention further provides kits comprising such compositions.
Abstract: The invention provides novel pharmaceutical compositions for the treatment of keratoconjunctivitis sicca comprising liquid vehicles which include one or more semifluorinated alkanes. The compositions incorporate an active ingredient selected from the group of macrolide immunosuppressants. They can be administered topically into the eye. The invention further provides kits comprising such compositions.
Type:
Application
Filed:
December 13, 2010
Publication date:
September 27, 2012
Applicant:
NOVALIQ GMBH
Inventors:
Bastian Theisinger, Sonja Theisinger, Bernhard Günther
Abstract: The invention provides novel pharmaceutical compositions comprising the active ingredient propofol. Preferably, propofol is dissolved in at least one semifluorinated alkane. The compositions, which are preferably liquid or gel-like, may optionally comprise further excipients. They may be used as fill material in capsules, as buccal or nasal sprays, or as aerosols for pulmonary administration. They are particularly useful for the transmucosal administration of propofol.
Abstract: The invention provides novel pharmaceutical compositions of macrolide immunosuppressants. The compositions comprise a hydrophilic component, a lipophilic component, and an amphiphilic component. Preferably, the compositions are formulated as liquid microemulsion. Furthermore, the invention provides uses of such compositions, such as for the topical treatment of inflammatory and autoimmune diseases. Methods for preparing the compositions are also provided.
Abstract: Use of a composition which contains at least one semifluorinated alkane compound and at least one liquid siloxane, wherein the composition is of a density in a range of 0.8 to 1.5 g/cm3, for preserving organs or limbs.
Type:
Grant
Filed:
November 23, 2006
Date of Patent:
October 4, 2011
Assignee:
NOVALIQ GmbH
Inventors:
Hasso Meinert, Bernhard Günther, Wilfried Hiebl, Bastian Mühling, Daniel Brandhorst
Abstract: A medical aid for the direct transport of at least one drug into lung regions of a patient, wherein provided as the carrier for at least one active substance is at least one semifluorinated alkane in which the at least one active substance is purely physically dissolved in a homogeneous phase.
Abstract: Use of a composition which contains at least one semifluorinated alkane compound and at least one liquid siloxane, wherein the composition is of a density in a range of 0.8 to 1.5 g/cm3, for preserving organs or limbs.
Type:
Application
Filed:
November 23, 2006
Publication date:
September 10, 2009
Applicant:
Novaliq GmbH
Inventors:
Hasso Meinert, Bernhard Günther, Wilfried Hiebl, Bastian Mühling, Daniel Brandhorst